15th Sep 2014 10:12
LONDON (Alliance News) - Oxford Pharmascience Group PLC said Monday it has successfully produced a reduced-gastric-irritation, taste-masked version of pain relief drug naproxen, and is now progressing this product to manufacturing scale up and clinical proof of concept.
The company saw positive results from a clinical study of reduced gastric irritation ibuprofen in July, and has used the technology from this product to work on other commonly used non-steriodal anti-inflammatory drugs (NSAIDs), including naproxen.
It is also pursuing a version of diclofenac and aspirin.
Oxford Pharmascience said its version of naproxen aims to reduce gastrointestinal side effects from its use, and is taste-masked to mitigate the unpleasant taste of the medicine.
"We believe that moving forward with the four main NSAIDs in parallel represents a more compelling proposition for adding further shareholder value, as it increases the potential licensing scope and value of applying our technology across multiple products in the anti-inflammatory pain relief category," said Chief Executive Marcelo Bravo in a statement.
Shares in Oxford Pharmascience were trading up 0.5% at 4.24 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Pharmascience Group